Hospital
Indian River Memorial Hospital INC
Indian River Memorial Hospital INC was paid $9.27M by Medicaid between Jan 2018 and Nov 2024, across 198 billing codes. Its largest line is 99285, emergency room visit (most serious) — 17% of everything it billed.
33Billing provider infoINDIAN RIVER MEMORIAL HOSPITAL INC
VERO BEACH, FL 32960
VERO BEACH, FL 32960
33aNPI1376512988assigned 03/16/2006
33bProvider typePsychiatric Hospital Unit
28Total paid$9.27M
24GClaims460,295
24DCodes billed198
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Psychiatric Hospital Unit providers in Florida
Rank by total paid#5 of 15
Median peer was paid$7.13M
This provider vs. median1.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LARAWAY, DENNIS controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 55,847 | $836K | |
| 2019 | 109,037 | $1.98M | |
| 2020 | 83,118 | $1.27M | |
| 2021 | 95,368 | $1.84M | |
| 2022 | 79,051 | $1.99M | |
| 2023 | 27,875 | $1.02M | |
| 2024incomplete | 9,999 | $317K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 17% | 14,443 | 11,562 | $1.58M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 17,007 | 13,966 | $1.19M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 17,635 | 15,224 | $1.09M |
| 80053 | Comprehensive metabolic panel | 6.4% | 31,202 | 22,918 | $594K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.8% | 6,581 | 5,891 | $352K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 3.6% | 25,854 | 15,815 | $334K |
| 96361 | Intravenous infusion, hydration; each additional hour | 3.4% | 6,990 | 5,316 | $311K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.8% | 3,562 | 3,261 | $262K |
| 59025 | Fetal non-stress test | 2.7% | 2,852 | 1,808 | $248K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.6% | 3,941 | 3,304 | $240K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.5% | 4,994 | 2,670 | $231K |
| G0378 | Hospital observation service, per hour | 1.8% | 4,342 | 3,277 | $165K |
186 more codes
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.7% | 3,308 | $154K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.2% | 2,460 | $112K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.0% | 5,340 | $95K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 4,012 | $92K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 7,025 | $86K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 862 | $82K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 7,949 | $75K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,530 | $74K |
| 82948 | <1% | 5,664 | $71K | |
| 84702 | <1% | 3,691 | $70K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,142 | $68K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,619 | $64K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 31,046 | $63K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,813 | $58K |
| 85610 | <1% | 10,891 | $57K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,715 | $56K |
| 81025 | <1% | 7,389 | $52K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,702 | $52K |
| 84484 | <1% | 7,850 | $48K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 7,750 | $47K |
| 87420 | <1% | 864 | $46K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,364 | $46K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 15,601 | $45K |
| 96367 | <1% | 742 | $45K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 1,307 | $44K |
| 71045 | Radiologic examination, chest; single view | <1% | 10,012 | $36K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,955 | $33K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,653 | $31K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 10,401 | $30K |
| 81001 | <1% | 16,393 | $28K | |
| 81003 | <1% | 4,923 | $27K | |
| 85730 | <1% | 6,467 | $27K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,126 | $26K |
| 87400 | <1% | 2,816 | $26K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,351 | $26K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 547 | $24K |
| 85027 | <1% | 5,569 | $24K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 7,336 | $23K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,737 | $21K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,508 | $21K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,245 | $20K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 476 | $20K |
| 83735 | <1% | 7,665 | $20K | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,533 | $20K |
| 83880 | <1% | 2,467 | $19K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 319 | $19K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 327 | $19K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,518 | $18K |
| 87070 | <1% | 2,867 | $16K | |
| 83605 | <1% | 1,829 | $15K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,301 | $14K |
| 74178 | <1% | 166 | $14K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,888 | $14K |
| 87081 | <1% | 641 | $13K | |
| 83690 | <1% | 4,482 | $13K | |
| 73630 | <1% | 368 | $12K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,286 | $12K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 642 | $11K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 224 | $11K |
| 86850 | <1% | 2,963 | $11K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,473 | $11K |
| 73610 | <1% | 261 | $10K | |
| 76801 | <1% | 958 | $10K | |
| 86900 | <1% | 3,012 | $10K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,077 | $9K |
| 73110 | <1% | 138 | $9K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 374 | $9K |
| 86901 | <1% | 3,013 | $8K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 131 | $8K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 440 | $7K |
| 73130 | <1% | 158 | $7K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,272 | $7K |
| 86140 | <1% | 1,262 | $7K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 243 | $6K |
| 73030 | <1% | 269 | $6K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,552 | $6K |
| 93971 | <1% | 294 | $6K | |
| 74018 | <1% | 362 | $5K | |
| 73562 | <1% | 218 | $5K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,476 | $5K |
| 94760 | <1% | 1,023 | $5K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 905 | $4K |
| 82150 | <1% | 144 | $4K | |
| 87077 | <1% | 2,162 | $4K | |
| 87186 | <1% | 2,956 | $4K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,122 | $4K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,653 | $4K |
| 80061 | Lipid panel | <1% | 946 | $3K |
| 85652 | <1% | 218 | $3K | |
| 96376 | <1% | 1,675 | $3K | |
| J3490 | Unclassified drugs | <1% | 383 | $3K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 936 | $3K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 89 | $2K |
| C1769 | Guide wire | <1% | 58 | $2K |
| 97161 | <1% | 59 | $2K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,408 | $2K |
| 96368 | <1% | 14 | $2K | |
| 87501 | <1% | 233 | $2K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,631 | $2K |
| 74019 | <1% | 83 | $2K | |
| 87040 | <1% | 753 | $2K | |
| 12011 | <1% | 13 | $2K | |
| 82553 | <1% | 588 | $2K | |
| 94726 | <1% | 61 | $2K | |
| 73080 | <1% | 26 | $1K | |
| 73502 | <1% | 229 | $1K | |
| 36591 | <1% | 100 | $1K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 87 | $1K |
| 82570 | <1% | 75 | $1K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 63 | $1K |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 79 | $1K |
| 95816 | <1% | 13 | $1K | |
| 72100 | <1% | 88 | $1K | |
| 87480 | <1% | 202 | $1K | |
| 85014 | <1% | 228 | $1K | |
| 71250 | <1% | 52 | $1K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 21 | $1K |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 558 | $991.96 |
| 84439 | <1% | 599 | $884.33 | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 91 | $874.31 |
| 88300 | <1% | 15 | $874.31 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 48 | $874.04 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 51 | $874.04 |
| 85379 | <1% | 308 | $809.08 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 119 | $727.34 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 231 | $510.25 |
| 29125 | <1% | 14 | $458.00 | |
| 82550 | <1% | 86 | $438.24 | |
| 84156 | <1% | 21 | $394.86 | |
| 93017 | <1% | 42 | $346.71 | |
| 82728 | <1% | 203 | $317.29 | |
| 85018 | <1% | 24 | $302.12 | |
| 84112 | <1% | 16 | $299.02 | |
| 94060 | <1% | 13 | $286.71 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 990 | $259.52 |
| 87088 | <1% | 510 | $251.09 | |
| J1815 | Injection, insulin, per 5 units | <1% | 761 | $234.26 |
| A9270 | Non-covered item or service | <1% | 400 | $227.71 |
| 97162 | <1% | 15 | $156.17 | |
| 94729 | <1% | 66 | $134.87 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 12 | $95.71 |
| 72131 | <1% | 15 | $94.85 | |
| 87660 | <1% | 207 | $75.07 | |
| Q0222 | Injection, bebtelovimab, 175 mg | <1% | 14 | $73.33 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 17 | $64.69 |
| 0002A | <1% | 160 | $60.72 | |
| 87205 | <1% | 186 | $50.96 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 135 | $42.23 |
| 83540 | <1% | 106 | $33.30 | |
| 88342 | <1% | 19 | $32.50 | |
| 83550 | <1% | 103 | $31.16 | |
| 84436 | <1% | 91 | $24.83 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 26 | $20.88 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 87 | $18.85 |
| 82962 | <1% | 423 | $16.97 | |
| 93799 | <1% | 231 | $16.86 | |
| 0001A | <1% | 193 | $14.37 | |
| 84132 | <1% | 84 | $10.71 | |
| 87510 | <1% | 202 | $9.65 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 72 | $4.55 |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 34 | $2.94 |
| 87430 | <1% | 152 | $2.28 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 0% | 197 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 244 | $0.00 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 17 | $0.00 |
| 00170 | Anesthesia for intraoral procedures, including biopsy | 0% | 100 | $0.00 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 0% | 16 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 18 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 24 | $0.00 |
| 96417 | 0% | 19 | $0.00 | |
| 97116 | 0% | 23 | $0.00 | |
| 73560 | 0% | 20 | $0.00 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 82 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 65 | $0.00 |
| 82077 | 0% | 59 | $0.00 | |
| 88304 | 0% | 14 | $0.00 | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 0% | 14 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 59 | $0.00 |
| 82533 | 0% | 14 | $0.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 45 | $0.00 |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 0% | 17 | $0.00 |
| 95012 | 0% | 16 | $0.00 | |
| 82607 | 0% | 18 | $0.00 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 33 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 20 | $0.00 |
| 83615 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLARAWAY, DENNIS (EXECUTIVE VP CHIEF FINANCE OFFICER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.